Susan F. Steinberg, MD

  • Professor of Molecular Pharmacology and Therapeutics
Profile Headshot


Academic Appointments

  • Professor of Molecular Pharmacology and Therapeutics

Credentials & Experience

Education & Training

  • BS, 1972 Biology, Massachusetts Institute of Technology
  • MD, 1976 Medicine, Harvard Medical School
  • Internship: 1977 Columbia Presbyterian Medical Center, NY
  • Residency: 1979 Columbia Presbyterian Medical Center, NY
  • Fellowship: 1982 Columbia Presbyterian Medical Center, NY

Committees, Societies, Councils


Diplomat, Internal Medicine, American Board of Internal Medicine

Diplomat, Endocrinology & Metabolic Diseases, American Board of Internal Medicine

American Federation for Clinical Research

American Society for Biochemistry and Molecular Biology

American Society for Pharmacology and Experimental Therapeutics

American Heart Association, Fellow of the Council on Basic Cardiovascular Sciences

Fellow of the International Society for Heart Research (FISHR)


Member, Program Project Study Section A, USPHS-NHLBI 1992-1996

Molecular Signaling Study Committee, Basic Science Council, American Heart Association 1995-2000

American Heart Association, Northeast Research Consortium Peer Review Group, Cardiovascular Physiol & Pharm, Molecular Biology of Muscle, and Molecular Signaling. 1998-2002

Ad Hoc Reviewer, Cardiovascular and Renal (CVB) Study Section, USPHS-NHLBI 1999

Howard Hughes Medical Institute Research, Medical Student Fellowship Awards Review Panel 1999-2000

Cardiovascular A (CVA) Study Section, Member, USPHS-NHLBI 2000-2004

Chair, NIH Scientific Review Group ZRG1 CVRS-C 02 M, Cardiac Therapies 2010

Program Committee, Basic Science Council, American Heart Association 1994-1997

Abstract Reviewer, American Heart Association Scientific Sessions 1989-2001, 2006-2009, 2011, 2014

Editorial Boards:

Circulation Research 1995-2013

Journal of Cardiovascular Pharmacology 1998-present

Journal of Molecular & Cellular Cardiology 2000-present

American Journal of Physiology 1999-2015

Circulation 2004-2016

Journal of Biological Chemistry 2006-2011

Journal of Cardiovascular Pharmacology, Associate Editor 2008-present

Faculty of 1000, Cardiovascular Physiology 2005-present

Faculty of 1000, Pharmacology & Drug Discovery Advisory Board 2009-present

Columbia University; Department of Medicine, Graduation prizes committee 2002-2004

Molecular Pharmacology Division of ASPET; Secretary-Treasurer 2003-2005

Women in Pharmacology Committee – ASPET 2003-2010

American Heart Association: Chair - Scientific Conference on Molecular Mechanisms of Growth, Death and Regeneration in the Myocardium (with Dr. David Kass) August, 2005

New York Academy of Medicine, Chair, Selection Committee for the Glorney-Raisbeck Fellowship in Cardiovascular Diseases 2005-2008

American Heart Association - Chair Northeast 5B Study Group, Basic Cell and Molecular Biology, Molecular Signaling and Cardiovascular Development April, 2005

American Heart Association, National, Research Committee, Strategic Planning Subcommittee 2005-2008

Chair Stem Cell Task Force 2007-2009

International Society for Heart Failure Research, North American Section Council Member 2006-2012

Nominating Committee for ISHR, North American section officers 2009-2011

North American section program/steering committee 2009-2011

Katz Prize Selection Committee, American Heart Association, Council on Basic Cardiovascular Science 2008-2012

Cardiac Contractility, Hypertrophy, and Failure (CCHF), Study Section, member USPHS-NHLBI 2012-2015

Committee on Appointments and Promotions, Columbia University 2007-2012

Dean’s Committee on Faculty Diversity, Columbia University 2012-present

American Heart Association – Basic Cardiovascular Science Council, Leadership Committee 2014-2018

Columbia University Senate 2016-2018

Honors & Awards

Thomas Smith Memorial Lecture, American Heart Associattion, 2019


The studies in my laboratory aim to identify the mechanisms that underlie the physiologically important changes in cardiomyocyte adrenergic receptor responsiveness that accompany normal cardiac development, that influence the evolution of heart failure, or that contribute to cardiac injury in the setting of ischemia-reperfusion injury and oxidative stress. Our studies take advantage of a wide range of reductionist molecular and cell biological approaches in both cell culture and in vitro models to study the expression and subcellular localization of adrenergic receptor subtypes, to identify the adrenergic receptor binding partners and effectors that dictate signaling specificity in cardiomyocytes, and to understand the molecular basis for catecholamine-dependent cardiomyocyte remodeling. One area of particular interest has been the stimulus- (in some cases redox-) dependent post-translational modifications on signaling kinases such as protein kinase C and protein kinase D that alter their enzymology. We also have identified post-translational processing (involving an O-glycan-regulated proteolytic cleavage) of the beta1-adrenergic receptor N-terminus as a mechanism that calibrates signaling output to downstream effector responses. In both cases, these studies identify novel molecular determinants that can serve as druggable targets.

Selected Publications

Steinberg SF. N-tertaining a new signaling paradigm for the cardiomyocyte β1-adrenergic recepetor. J Cardiovasc Pharmacology (in press) 2022.

Zhu J and Steinberg SF. Trypsin cleavage of the β1-adrenergic receptor. Am J Physiol 322:H486-491, 2022

Zhu J and Steinberg SF. β1-adrenergic receptor N-terminal cleavage by ADAM17; the mechanism for redox-dependent downregulation of cardiomyocyte β 1-adrenergic receptors. J Mol Cell Cardiol 154:70-79, 2021.

Steinberg SF. Decoding the cardiac actions of protein kinase D isoforms. Mol Pharm 100:558-567, 2021

Alter S, Zimmer Ad, Park M, Gong J, Caliebe A, Fölster-Holst R, Torrelo A, Colmenero I, Steinberg SF, Fischer J. Telangiectasia - Ectodermal Dysplasia-Brachydactyly-Cardiac Anomaly-Syndrome is caused by de novo mutations in Protein Kinase D1. Human Genetics 58:415-421, 2021.

Park M and Steinberg SF. Carvedilol prevents redox inactivation of cardiomyocyte β1-adrenergic receptors. JACC: Basic to Translational Science 3:521-532, 2018.

Steinberg SF. Beta1-adrenergic receptor regulation revisited: the role of the extracellular N-terminus. Circ Res Viewpoint 123:1199-1201, 2018.

Steinberg SF. Post-translational modifications at the ATP-positioning G-loop that regulate protein kinase activity. Pharmacologic Research 135:181-187, 2018.

Park M, Reddy GR, Wallukat G, Xiang YK, and Steinberg SF. β1-adrenergic receptor O-glycosylation regulates N-terminal cleavage and signaling responses in cardiomyocytes. Scientific reports 7:7890, 2017.

Gong J and Steinberg SF. Cleavage alters the molecular determinants of protein kinase Cδ catalytic activity. Mol Cell Biol 37:e00324-17, 2017, 2017.

Qi W and Steinberg SF. Phos-tag SDS-PAGE resolves agonist- and isoform-specific activation patterns for PKD2 and PKD3 in cardiomyocytes and cardiac fibroblasts. J Mol Cell Card 99:14-22, 2016.

Gong J, Yao Y, Zhang P, Udayasuryan B, Komissarova E, Zhang F, Chen J Sivaramakrishnan S Van Eyk JE and Steinberg SF. The C2 domain and altered ATP-binding loop phosphorylation at Ser357 mediate the redox-dependent increase in protein kinase C-delta activity. Mol Cell Biol 35:1727-1740, 2015.